ABSTRACT Background. Our previous study indicated that gene expression profiling of intestinal metaplasia (IM) or spasmolytic polypeptide-expressing metaplasia (SPEM) can identify useful prognostic markers of early-stage gastric cancer, and seven metaplasia biomarkers (MUC13, CDH17, OLFM4, KRT20, LGALS4, MUC5AC, and REG4) were selectively expressed in 17-50% of gastric cancer tissues. We investigated whether the combined expression of these metaplasia biomarkers could predict the prognosis of advanced stage gastric cancer. Methods. The expression of seven metaplasia biomarkers was evaluated immunohistochemically using tissue microarrays comprised of 450 gastric cancer patients. The clinicopathologic correlations and the prognostic impact were analyzed according to the expression of multiple biomarkers.
group B was significantly poorer than that of group A by multivariate analysis. Conclusions. The combined loss of expression of multiple metaplasia biomarkers is considered an independent prognostic indicator in undifferentiated or stage II/III gastric cancer.
Multiple gene expression profiling using cDNA microarrays and/or tissue arrays has been widely used for the prediction of prognosis in breast cancer, lung cancer, lymphoma, and colon cancer. [1] [2] [3] [4] Whereas the application of cDNA microarrays allows for the precise analysis of the expression pattern of many suspected genes in each tissue, tissue microarray technology can accelerate the complex tissue analysis of genes with clinicopathologic findings, such as diagnostic or prognostic data. [5] [6] [7] Recently several studies have reported useful biomarkers that might be related to gastric cancer as well as premalignant gastric lesions. 8, 9 Compared with the cancer tissue, which often shows heterogenous cell morphologies, the metaplastic lineages often are more uniform, even compared with the lineages from the normal stomach. 10 We have previously reported gene microarray studies analyzing laser capture-microdissected samples of both intestinal metaplasia (IM) and spasmolytic polypeptideexpressing metaplasia (SPEM) in humans as well as SPEM in mice. 11, 12 Using this approach, we also reported that CDH17, which was selectively expressed in both IM or SPEM, is a single, independent metaplasia biomarker for the prediction of prognosis in stage I or node-negative gastric cancer. various interfering conditions. 8, [13] [14] [15] Nevertheless, several studies have employed multiple genes or proteins as useful biomarkers for tumor progression as well as cancer prediction. 16, 17 However, few previous investigations have evaluated how markers of metaplasia could reflect prognosis in gastric cancer with advanced stages. In our previous studies about biomarkers of metaplasia, we found that seven proteins selectively expressed in IM or SPEM, including MUC13, CDH17, OLFM4, KRT20, LGALS4, MUC5AC, and REG4, also were expressed in 17-50% of human gastric cancer tissues compared with normal gastric mucosa. 11 The purpose of this study was to analyze the expression profiles of multiple proteins selectively expressed in IM and/or SPEM as well as gastric cancer and to investigate the prognostic impact of the combination of protein biomarkers in advanced stage gastric cancer.
METHODS
To identify the expression profiles of seven metaplasia biomarkers, MUC13, CDH17, OLFM4, KRT20, LGALS4, MUC5AC, and REG4, which were found from the previous study, immunostaining was performed on tissue microarray (TMAs) comprised of 450 gastric adenocarcinomas resected at Seoul National University Hospital in 2004 (SNUH-2004-GC; SuperBioChips. During the operation, D2 lymph node dissection was performed on the patients who underwent curative resection, irrespective of the type of gastrectomy. 18 None of the patients received neoadjuvant chemotherapy or radiation therapy before the surgery. Adjuvant chemotherapy, most commonly a 5-fluorouracil-based combination was usually indicated in patients with stage II or higher stages.
In addition to the three proteins (CDH17, MUC13, and OLFM4) that were evaluated in our previous study, we performed immunohistochemical staining for an additional four proteins (MUC5AC, KRT20, LGALS4, and REG4) with commercially available antibodies (Table 1) . 11 TMAs were assembled according to the following procedure: core tissue biopsies (diameter 2 mm) were obtained from individual paraffin-embedded gastric tumors (donor blocks) and arranged in new recipient paraffin blocks (tissue array blocks) using a trephine apparatus (Superbiochips Laboratories, Seoul, Korea). The tissue array blocks contained up to 60 cores on 8 arrays, for a total of 450 cases for immunohistochemistry (IHC) staining. Tumors occupying more than 10% of the core area were considered adequate. Each paraffin block contained internal controls, which consisted of nonneoplastic gastric mucosa from the body and antrum as well as intestinal metaplasia. IHC was performed using a Leica Bond-max automated immunostainer (Leica Microsystems, Newcastle, UK), as described by the manufacturer's protocol.
After tissues were sampled from in each core, staining patterns were scored as 0 (negative), 1 (weakly to moderately positive), and 2 (strongly positive), which was separated into negative (0) and positive (1 or 2) groups. For statistical analysis, cellular staining was considered positive only when more than 10% of the total cancer cells within one core were stained. The immunohistochemical staining for each core was assessed and scored without any clinical information.
The clinicopathologic and prognostic significance of the expression of these proteins was analyzed using SNUH-2004-GC TMA for the following variables: age, sex, the WHO differentiation, the Lauren classification, tumor size, the number of metastatic lymph nodes and retrieved lymph nodes, lymphatic/venous/perineural invasion, TNM stage, radicality, and disease-specific survival. 19 Regarding the WHO differentiation, papillary, well-differentiated, and moderately differentiated types were categorized as the differentiated group, and poorly differentiated, signet ring cell, and mucinous types were categorized as the undifferentiated group.
The correlations between multiple protein staining results and clinicopathologic characteristics were analyzed. The Student's t test and Chi-square test were used for comparative statistical analyses. Disease-specific survival rates were evaluated by the Kaplan-Meier method and the prognoses were compared using the log-rank test. All clinicopathologic variables as well as the expression of the combination of multiple protein biomarkers with a log-rank P value \0.05 were entered into the multivariate analysis. The Cox proportional hazards model was used for the multivariate analysis to identify independent prognostic factors. All tests were two-sided and were performed at the 5% level of significance using SPSS version 17.0 (SPSS Inc., Chicago, IL). The median follow-up period was 49.1 (range, 0.4-64.4) months. This study was approved by the Institutional Review Board of Seoul National University Hospital (H-1102-062-351). Table 2 shows the demographic data for the patients samples on the SNUH-2004-GC tissue microarray, including age, sex, tumor location, tumor size, number of metastatic lymph nodes, number of retrieved lymph nodes, Lauren classification, WHO classification, lymphatic/ venous/perineural invasion, and TNM stage. The staining patterns of MUC13, CDH17, OLFM4, KRT20, LGALS4, MUC5AC, and REG4 in the SNUH-2004-GC TMA are shown in Fig. 1 .
Among the biomarkers tested, MUC13 showed two distinct expression patterns: one is the membranous type which is usually expressed in intestinal type tumors (MUC13m), and the other is the diffuse cytoplasmic type (MUC13c) as previously described.
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Among the seven proteins, four markers, including MUC13m, CDH17, REG4, and LGALS4, were significantly related to the prognosis of gastric cancer by univariate survival analysis, whereas MUC13c, OLFM4, KRT20, and MUC5AC were not significantly related to survival rates (Fig. 2) . The correlations between the expression profiles and clinicopathologic parameters of former four protein markers were analyzed ( Table 3 ). The loss of CDH17 expression was more frequently associated with undifferentiated type and diffuse type cancer. The loss of REG4 expression showed significant association with younger age, diffuse type cancer, perineural invasion, advanced T stage, and M1 stage. The loss of LGALS4 expression was significantly associated with lymphatic invasion, N stage, and M stage. All clinicopathologic variables except for lymphatic or venous invasion were significantly associated with MUC13m expression.
The combined expression of CDH17, REG4, LGALS4, and MUC13m was divided into five groups according to expression patterns. No expression of the four protein markers was found in 56 cases (14.2%); one marker was seen in 67 cases (17%), two in 106 cases (27%), three in 101 cases (25.7%), and four in 63 cases (16%). Among CDH17, REG4 and LGALS4, and MUC13m, the combined expression of 3 or 4 protein biomarkers was classified as the positive expression group (group A) and that of two or fewer protein markers was classified as the expression loss group (group B). Group B showed a younger age population, undifferentiated and diffuse type tumors, larger tumor size, larger number of metastatic lymph nodes, more frequent lymphatic/perineural invasion, less frequent R0 resection, and more advanced stage (Table 4) . Regarding disease-specific survival analysis, the combined expression loss of protein biomarkers was significantly correlated with the prognosis, and group B showed a significantly poorer survival rate than group A (Fig. 3) . By subgroup analysis, group B showed a significantly poorer prognosis than group A for undifferentiated cancer, CT2 advanced gastric cancer (AGC), and node-positive (N?) cancer (Fig. 4) . For TNM stage, even though there was no significant difference between the two groups in both stage I and stage IV cancers, group B showed a significantly poorer prognosis than group A for stages II/III (Fig. 5) . In multivariate analysis, the combined loss of expression for MUC13m, CDH17, REG4, and LGALS4 proved to be an independent prognostic factor in undifferentiated cancer, AGC, N? cancer, and stage II/III cancer (Table 5 ).
DISCUSSION
The current study revealed that the profiling of the combined expression of four metaplasia biomarkers could be used as an independent prognostic marker in undifferentiated type gastric cancer or in AGC. Little is known about the genetic pathway or the mechanism for carcinogenesis or tumor progression in undifferentiated gastric cancer, especially compared with that of differentiated gastric cancer. 20, 21 During tumor progression, gastric adenocarcinomas tend to lose differentiation markers present in metaplasia, leading to less differentiated phenotypes.
14 Other investigations also have suggested that the predominant histologic type may be altered from the differentiated to the undifferentiated type with increasing tumor size and the progression of the tumor. 22, 23 Certain undifferentiated-type carcinomas may derive from the differentiated type tumors through progressive loss of cellto-cell adhesion by the loss of cell-adhesion molecules. 14 The results of these previous reports and our present findings suggest that the cumulative loss of the expression of differentiation-related proteins during the progression of the tumor may cause differentiated gastric cancer to evolve into the undifferentiated type, resulting in a poorer prognosis.
The proteins biomarkers utilized in our investigations have similar functions related to cell-to-cell adhesion or differentiation. CDH17 (cadherin-17, liver-intestine cadherin) is a member of the cadherin family and works as a functional calcium-dependent cell adhesion molecule.
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We have previously reported that CDH 17 is a promising prognostic marker for early-stage gastric cancer.
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The human MUC13 gene encodes an epithelial and hemopoietic transmembrane mucin, and it is most highly expressed in epithelial tissues, especially those of the gastrointestinal and respiratory tracts 25 In gastric cancer, MUC13 is a good differentiation marker for the gastrointestinal mucosa and has distinct roles in the carcinogenesis of diffuse type gastric cancer. 26 LGALS4, a novel biomarker for gastric cancer, belongs to a subfamily of galactins, which is composed of two carbohydrate recognition domains within the same peptide and is involved in a number of biological steps, including cell to cell adhesion, growth regulation, and signaling pathways. 27, 28 Within human epithelial cancer cell lines, LGALS4 is overexpressed in highly differentiated cell lines, but is absent in less differentiated lines. 28 Balan et al. 29 also reported LGALS4 as a useful tumor marker for gastric cancer progression and the potential for lymph node metastasis. Based on these previous studies and the results of our study, it appears that LGALS4 is expressed in more differentiated cancers, particularly group A patients in our study, and loss of protein expression is associated with tumor progression or dedifferentiation in group B patients. The regenerating gene (REG) was originally isolated from regenerating rat pancreatic islets and is a trophic factor for both islet cells and gastric epithelial cells. 30, 31 Human REG4 is expressed in gastrointestinal cancers, pancreas cancer, and carcinoid tumors, and it is associated with intestinal metaplasia or increased cellular differentiation in the gastric cancer. 32 The biological function of REG4 is poorly understood. REG4 has been known to enhances peritoneal metastasis in gastric cancer or to be involved in apoptosis resistance because of its 5-FU resistance. 15, 33 On the other hand, REG4 expression has often been considered a good differentiation biomarker for gastric precancerous lesions. 32 These results suggest that Pearson's correlation is significant at the 0.05 level
Pearson's correlation is significant at the 0.01 level REG4 may promote differentiation in metaplasia while enhancing carcinogenesis or tumor progression in gastric cancer with more advanced stage, which highlights the difficulties of using a single marker in prognostic studies.
In this study, we found that the cumulative expression of cell-to-cell adhesion or differentiation related proteins is an independent prognostic factor in not only undifferentiated gastric cancer but also AGC or N? gastric cancer. Cell-tocell adhesion molecule expression may be influenced by maturation as well as malignant transformation of cells, and down-regulation of cell adhesion molecules may be a common event in the carcinogenesis of gastric cancer. 34, 35 Previous studies have demonstrated that the loss of cell adhesion molecule expression was significantly related to the loss of contact inhibition of growth, cellular dedifferentiation, and the disorganization of tissue architecture and is potentially important in the formation of metastases from adenocarcinoma. [35] [36] [37] [38] In addition to the proteins assessed in our study, a number of cell-adhesion proteins, including E-cadherin, dysadherin, CD44 focal adhesion kinase, syndecan-1, and integrins have been associated with the prognosis of gastric cancer. 17, 37, [39] [40] [41] Unlike these previous studies, we have postulated that the cumulative loss of expression of adhesion or differentiation protein biomarkers, which were selectively expressed in premalignant metaplasia, could induce the disorganization of tissue architecture as well as cellular dedifferentiation, elevate the invasive potential into adjacent tissue including lymphatics, and influence the behavior of AGC or N? cancer.
In the present study, protein expressions in each gastric cancer case are based on the immunohistochemical analysis of one core on TMAs. In terms of the possible diversity of histological components or molecular abnormality of advanced gastric cancer, we have already shown excellent agreement in the staining results of the different intratumoral areas of gastric carcinomas, including advanced gastric cancer, and the effects of intratumoral heterogeneity can be averaged out in such a large scale analysis as our study. 7, 42, 43 Unfortunately, we could not demonstrate an independent prognostic factor for each TNM stage. However, stage I may be too early to show the differences in protein expression levels of various cell-to-cell adhesion molecules or differentiation markers, whereas stage IV in the current UICC/AJCC TNM staging system is already too advanced and incurable to reflect a prognostic difference. 19 According to the current treatment strategies, stage II/III are curable advanced stages that are continuously being investigated and challenged. Therefore, compared with stage I or IV, an independent prognostic factor in advanced stage II/III can offer much more important clinical value.
In conclusion, the loss of the combined expression of metaplasia biomarkers, including CDH17, MUC13m, 
